文献速递心力衰竭与心肌病冠心病

心肌炎相关坏死性冠状动脉血管炎:发病率、病因和结局

Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome.
PubMed 文献 · Eur Heart J · 2021-01-01

免疫抑制治疗使88%的NCV患者和86%的病毒阴性心肌炎患者心功能改善。

要点

  • 活检证实的心肌炎中NCV检出率为1.5%,院内死亡率高达24%。
  • NCV病因包括感染性和免疫介导性,免疫介导者TLR4过表达且抗心脏自身抗体阳性。
  • 免疫抑制治疗可改善多数NCV患者的心功能,应答率达88%。

核心结论

  • 坏死性冠状动脉血管炎在活检证实的心肌炎中检出率为1.5%,院内死亡率为24%,免疫介导途径与免疫抑制治疗获益相关。

研究设计与样本

  • 回顾性分析1916例活检证实的心肌炎患者,其中30例检出NCV,并设60例心肌炎患者和30例对照进行比较。
  • 对心内膜心肌样本行免疫组化检测TLR4,实时PCR检测病毒基因组,血清检测抗心脏自身抗体及细胞因子。
  • NCV队列随访6个月,采用2D超声和/或心脏磁共振评估,左室射血分数增加≥10%定义为治疗应答。

主要发现

  • NCV病因包括感染性(10%)、免疫介导性(胸部创伤3%、药物过敏7%、高嗜酸性粒细胞综合征3%、原发性自身免疫病33%、特发性44%)。
  • 免疫介导性NCV和病毒阴性心肌炎患者抗心脏自身抗体阳性,抗体阳性NCV患者血管壁呈自身反应性。
  • 免疫介导性NCV中TLR4过表达,病毒性NCV中TLR4几乎检测不到。
  • NCV患者IL-1β显著高于心肌炎患者,院内死亡率24%对比心肌炎队列1.5%。

临床怎么用

  • 对活检证实的心肌炎患者应警惕NCV,尤其表现为心力衰竭或电不稳定者。
  • 识别免疫介导途径(病毒阴性、TLR4阴性、自身抗体阳性)可指导免疫抑制治疗决策。
  • NCV患者院内死亡风险高,需密切监测和积极管理。

局限性

  • 回顾性研究设计,样本量较小(NCV仅30例)。
  • 单中心研究,结论外推需谨慎。
  • 免疫抑制治疗方案未详细描述,随访仅6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Necrotizing coronary vasculitis (NCV) is a rare entity usually associated to myocarditis which incidence, cause, and response to therapy is unreported. METHODS AND RESULTS: Among 1916 patients with biopsy-proven myocarditis, 30 had NCV. Endomyocardial samples were retrospectively investigated with immunohistochemistry for toll-like receptor 4 (TLR4) and real-time polymerase chain reaction (PCR) for viral genomes. Serum samples were processed for anti-heart autoantibodies (Abs), IL-1β, IL-6, IL-8, tumour necrosis factor (TNF)-α. Identification of an immunologic pathway (including virus-negativity, TLR4-, and Ab-positivity) was followed by immunosuppression. Myocarditis-NCV cohort was followed for 6 months with 2D-echo and/or cardiac magnetic resonance and compared with 60 Myocarditis patients and 30 controls. Increase in left ventricular ejection fraction ≥10% was classified as response to therapy. Control endomyocardial biopsy followed the end of treatment. Twenty-six Myocarditis-NCV patients presented with heart failure; four with electrical instability. Cause of Myocarditis-NCV included infectious agents (10%) and immune-mediated causes (chest trauma 3%; drug hypersensitivity 7%; hypereosinophilic syndrome 3%; primary autoimmune diseases 33%, idiopathic 44%). Abs were positive in immune-mediated Myocarditis-NCV and virus-negative Myocarditis; Myocarditis-NCV patients with Ab+ presented autoreactivity in vessel walls. Toll-like receptor 4 was overexpressed in immune-mediated forms and poorly detectable in viral. Interleukin-1β was significantly higher in Myocarditis-NCV than Myocarditis, the former presenting 24% in-hospital mortality compared with 1.5% of Myocarditis cohort. Immunosuppression induced improvement of cardiac function in 88% of Myocarditis-NCV and 86% of virus-negative Myocarditis patients. CONCLUSION: Necrotizing coronary vasculitis is histologically detectable in 1.5% of Myocarditis. Necrotizing coronary vasculitis includes viral and immune-mediated causes. Intra-hospital mortality is 24%. The immunologic pathway is associated with beneficial response to immunosuppression.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Frustaci A, Alfarano M, Verardo R, et al. Myocarditis-associated necrotizing coronary vasculitis: incidence, cause, and outcome. Eur Heart J. 2021. PMID: 33355356. doi:10.1093/eurheartj/ehaa973

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。